| 1 |
Alves LB, Moura AC, Amorim Dos Santos J, Borges GA, Guerra ENS. Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review. Toxicol In Vitro 2023;88:105558. [PMID: 36681288 DOI: 10.1016/j.tiv.2023.105558] [Reference Citation Analysis]
|
| 2 |
Vigoda M, Mathieson C, Evans N, Hale C, Jennings J, Lucero O, Jeng S, Bottomly D, Clayburgh D, Andersen P, Li R, Petrisor D, Tyner JW, McWeeney S, Kulesz-Martin M. Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. Cancer Biol Ther 2022;23:310-8. [PMID: 35343367 DOI: 10.1080/15384047.2022.2055420] [Reference Citation Analysis]
|
| 3 |
Thiruthaneeswaran N, Bibby BAS, Yang L, Hoskin PJ, Bristow RG, Choudhury A, West C. Lost in application: Measuring hypoxia for radiotherapy optimisation. Eur J Cancer 2021;148:260-76. [PMID: 33756422 DOI: 10.1016/j.ejca.2021.01.039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Anderson K, Ryan N, Alkhimovitch A, Siddiqui A, Oghumu S. Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. Cancers (Basel) 2021;13:953. [PMID: 33668795 DOI: 10.3390/cancers13050953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Wilson GD, Wilson TG, Hanna A, Dabjan M, Buelow K, Torma J, Marples B, Galoforo S. Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. Clin Transl Radiat Oncol 2021;26:15-23. [PMID: 33251343 DOI: 10.1016/j.ctro.2020.11.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 6 |
Glorieux M, Dok R, Nuyts S. The influence of PI3K inhibition on the radiotherapy response of head and neck cancer cells. Sci Rep 2020;10:16208. [PMID: 33004905 DOI: 10.1038/s41598-020-73249-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 7 |
Hintelmann K, Kriegs M, Rothkamm K, Rieckmann T. Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. Front Oncol 2020;10:1260. [PMID: 32903756 DOI: 10.3389/fonc.2020.01260] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 8 |
Lee MJ, Jin N, Grandis JR, Johnson DE. Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. Biochim Biophys Acta Mol Cell Res 2020;1867:118679. [PMID: 32061630 DOI: 10.1016/j.bbamcr.2020.118679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 9 |
Wilson TG, Hanna A, Recknagel J, Pruetz BL, Baschnagel AM, Wilson GD. Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. Head Neck 2020;42:153-62. [PMID: 31657099 DOI: 10.1002/hed.25983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
